AngioDynamics Inc

AngioDynamics, Inc. drives medical innovation with diagnostic and interventional devices, yet faces profitability challenges—see how its strategy could reshape its market position and future growth prospects.

AngioDynamics Inc. reported strong Q1 2026 earnings, with revenue up 12.2% and EPS improving by 75%, leading the company to raise its full-year guidance and its stock price to gain 8-11% in intraday trading.

AngioDynamics Inc. is expected to report a loss of $0.12 per share in its Q1 earnings, with analysts projecting a year-to-date loss of $0.31 per share, raising concerns about the company’s financial trajectory and investor confidence.

AngioDynamics Inc. faces a critical earnings outlook, with analysts predicting a loss per share and revenue growth that falls short of previous year’s numbers, leaving the company’s future uncertain.

AngioDynamics Inc, a healthcare equipment company, faces significant financial turbulence despite its innovative products and commitment to improving patient outcomes.